# Childhood Pneumonia

# Clinical presentation and Early Detection & Referral

16.01.2025

### Dr Kamal Kumar Singhal

DCH, MD, DM (Pediatric Pulmonology)

Professor, Department of Pediatrics

Lady Hardinge Medical College and Kalawati Saran Children's Hospital,

Shaheed Bhagat Singh Marg, New Delhi

# BURDEN

### • Globally

- Under 5 mortality: Major culprit
  - 14% deaths (WHO, 2019)
    - 2400 lives per day
    - 7.4 lakh per year
  - Pneumonia is a disease of poverty, a sign of inequality
    - 84% of child deaths from pneumonia in 30 countries mostly sub-Saharan Africa & Asia.

### • India

- 11 % of Global pneumonia deaths (UNICEF 2019)
  - Contributing factors: malnutrition, low birth weight, non exclusive breast feeding, lack of immunisation, indoor pollution and overcrowding.
- Regional Disparity: Kerala & Tamil Nadu reporting lower incidence rates

### What is Pneumonia?

# Pneumonia in Children: Definitions

- Pathologist's Definition:
  - Inflammation of the lung parenchyma, often caused by infection.
  - Histologically, it may show neutrophilic infiltration, edema, and alveolar hemorrhage depending on the causative organism.

- Radiologist's Definition:
  - Chest X-ray: New infiltrates, consolidation, or opacities in the lung fields.
  - The presence of air bronchograms or pleural effusion may suggest bacterial pneumonia, while lobar consolidation is indicative of more severe disease.

### We need a clinician's definition of Pneumonia !

What symptoms or complaints would prompt a parent to bring a child to a healthcare facility?

#### WHEEZE

#### HEADACHE

### TACHYPNEA BREATHLESSNESS

ABDOMINAL PAIN

## DIFFICULTY IN BREATHING CHEST PAIN



# Which equipment is most useful for diagnosing pneumonia in children?


• A) Pulse Oximeter and Thermometer



• B) Stethoscope








# Acute onset difficult breathing

### Respiratory

Asthma Bronchiolitis Viral croup Foreign body in the airways Pneumonia Effusion and Empyema Pneumothorax




### Non-Respiratory

Congestive heart failure Raised intra-cranial tension e.g. Meningitis Metabolic acidosis e.g. Diabetic Ketoacidosis, Renal Failure

# What is fast breathing?

# Fast breathing



To be counted for complete 60 seconds


# Respiratory rate

- <1 year age, RR of 70 breaths/min Sensitivity 63% and Specificity 89% for Hypoxaemia
- <5 years age, the WHO definitions for tachypnea Sensitivity 74% and specificity 67% for Radiographically-defined Pneumonia

Only fast breathing, No danger signs Radiological pneumonia 14%, lobar pneumonia 1% Work of breathing, compared to fast breathing, is more indicative of the likelihood of pneumonia

### Cough or Difficulty in breathing with


F



WHO/IAP

#### **F**

### Cough or Difficulty in breathing with



# Change in WHO classification

| <b>Clinical features</b>       | OLD                         | NEW                         |  |
|--------------------------------|-----------------------------|-----------------------------|--|
| Cough/cold                     | NO PNEUMONIA:<br>COUGH COLD | NO PNEUMONIA:<br>COUGH COLD |  |
| Fast Breathing                 | PNEUMONIA                   |                             |  |
| Chest indrawing                | SEVERE PNEUMONIA            | PNEUMONIA                   |  |
| General danger signs           |                             |                             |  |
| Severe respiratory<br>distress | VERY SEVERE<br>PNEUMONIA    | SEVERE PNEUMONIA            |  |
| Central cyanosis               |                             |                             |  |

### Change in treatment approach

| <b>Clinical featur</b>  | es OLD                 | NEW                          |
|---|------------------------|------------------------------|
| Cough/cold  | AdmissionXAntibioticsX | Admission X<br>Antibiotics X |
| Fast Breathing<br>Chest indrawing                                       | Antipiotics V          | Admission X<br>Antibiotics V |
| General danger sig<br>Severe respirator<br>distress<br>Central cyanosis | y                      | Admit v<br>Antibiotics v     |

### TREATMENT

| NO PNEUMONIA:<br>COUGH COLD | <u>No admission, No antibiotics</u><br>Soothe the throat and relieve cough with safe remedy<br>Advise when to return |
|-----------------------------|--|
| PNEUMONIA                   | No admission<br>Oral Antibiotics<br>Advise when to return  |
| SEVERE<br>PNEUMONIA         | <u>Admit</u><br><u>Injectable</u> Antibiotics<br>Oxygen if saturation < 90%.<br>Manage airway<br>Treat high fever    |

# What is the most prevalent cause of pneumonia throughout childhood?

A) Streptococcus pneumoniae
B) Mycoplasma pneumoniae
C) Viral infections
D) Haemophilus influenzae type b

# What is the most prevalent cause of pneumonia throughout childhood?

# A) Streptococcus pneumoniae B) Mycoplasma pneumoniae C) Viral infections D) Haemophilus influenzae type b

**Correct Answer:** C) **Viral** infections, such as *Respiratory Syncytial Virus* (RSV), Influenza, and Parainfluenza

| Most common agents causing CAP according to age       |  |  |  |         |  |  |
|---|--|--|--|---------|--|--|
| Newborn -3<br>months                                  | 1-6 months   | 6-12 months  | 1-5 yrs  | > 5 yrs |  |  |
| Group B Streptococcus<br>Enteric Gram-negative<br>RSV | Viruses<br>S pneumoniae<br>H influenzae<br>S aureus<br>M catarrhalis<br>Chlamydia trachomatis<br>Ureaplasma urealyticum<br>B pertussis | Viruses<br>S pneumoniae<br>H influenza<br>S. aureus<br>Moraxella catarrhalis | Viruses<br>M. Pneumoniae<br>C. pneumoniae<br>S. pneumoniae |         |  |  |

Viruses most prevalent cause of pneumonia throughout Childhood Streptococcus pneumoniae is the leading bacterial cause of CAP across all age groups

**Coinfections**, both with two or more viruses, or with viruses and bacteria, are very common. Coinfection rates up to 75% are commonly reported in infants

# If there is additional wheeze!

### Preschool Wheezer

- 1/4 infants- 1 episode by 9 months
- 1/2 children- 1 episode by 6yrs
- Tendency to reoccur.
- Onset is earlier in males

### Is there a role of Bronchodilator ?

Wheezing on auscultation - present in 60-80% of lower chest indrawing despite excluding asthma


Hazir T et al. New Outpatient Short-Course Home Oral Therapy for Severe Pneumonia Study Group. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet 2008; 371: 49-56.

#### Signs of pneumonia disappear in almost half of the cases with nebulization

Awasthi S, Agarwal G, Kabra SK, Singhi S, Kulkarni M, et al. (2008) Does 3-Day Course of Oral Amoxycillin Benefit Children of Non-Severe Pneumonia with Wheeze: A Multicentric Randomised Controlled Trial. PLoS ONE 3(4): e1991. doi:10.1371/journal.pone.0001991

#### Thus there should be a role !

| <i>Table 8. Differe</i><br>Diagnosis                        | Asthma   | -     | History of recurrent wheeze, chest tightness, some  |
|---|--|-------|---|
| Asthma  | Bronchiolitis  | _     | First episode of wheeze in a child aged < 2 years   |
| Bronchiolitis<br>Wheeze<br>associated with<br>cough or cold | Wheeze<br>associated with<br>cough or cold<br>Foreign body | -     | Wheeze always related to coughs and colds<br>No family or personal history of asthma, eczema,<br>hay-fever<br>Prolonged expiration<br>History of sudden onset of choking or wheezing<br>Wheeze may be unilateral<br>Air trapping with hyper-resonance and mediastinal shift<br>Signs of lung collapse: reduced air entry and impaired |
| Foreign body  | Pneumonia  | 1 1 1 | Fever<br>Coarse crackles<br>Grunting  |
| Pneumonia   |  |       | Organization  |



# Investigations

# Which of the following investigations are routinely indicated in children with non-severe community-acquired pneumonia?

A) Chest X-rayB) Microbiological investigationsD) Acute phase reactantsE) None of the above

# Which of the following investigations are routinely indicated in children with non-severe community-acquired pneumonia?

A) Chest X-rayB) Microbiological investigationsD) Acute phase reactantsE) None of the above

### Answer: E) None of the above

# Should I get a chest X ray in all ?

Should **not be a routine investigation in** community acquired pneumonia Signs and symptoms of pneumonia who are **not admitted** should **not have CXR** 

BTS. Thorax 2011;66:ii1eii23. doi:10.1136/thoraxjnl-2011-200598

Severe pneumonia: Chest X-ray to identify pleural effusion, empyema, pneumothorax, pneumatocoele, interstitial pneumonia or pericardial effusion

WHO

Seriously ill/Severe pneumonia
Complications suspected
Alternative diagnosis
Severe Acute Malnutrition
Post measles infections

# Should I do Microbiological investigations in all ?

Not Routinely in mild disease or those being treated in community Needed in: Who fail to improve and in those who have progressive deterioration

Available investigations

Blood culture: Positivity is uncommon

Nasopharyngeal secretions and nasal swabs: viral detection (PCR and/or immunofluorescence)

Serology: Acute and convalescent for respiratory viruses, Mycoplasma and Chlamydia

**Pleural fluid** for microscopy, culture, pneumococcal antigen detection and/or PCR

BTS. Thorax 2011;66:ii1eii23. doi:10.1136/thoraxjnl-2011-200598

### Can Acute phase reactants differentiate b/w Virus/ Bacterial/ atypical organism ?

Acute phase reactants Procalcitonin Cytokines C reactive protein (CRP) ESR and White blood cell count

# These reactants Individually and in combination

No clinical utility in distinguishing viral from bacterial infections Should not be tested routinely

BTS. Thorax 2011;66:ii1eii23. doi:10.1136/thoraxjnl-2011-200598


Acute phase reactants:
No clinical utility in distinguishing viral from bacterial
Should not be tested routinely
[A]

### •C reactive protein:


Not useful in uncomplicated pneumonia
Should not be measured routinely. [A+]

### Complications

Lung abscess



**Bronchiectasis** 



# When to refer to Intensive care units in acute pneumonia?

**Cyanosis:**  $\text{Spo}_2 < 92\%$  on  $\text{Fio}_2$  of  $\ge 0.50$ 

### Shock

Sustained tachycardia or Inadequate blood pressure or Need for pharmacologic support of blood pressure or perfusion

### Need for ventillatory support

Requires invasive ventilation

Requires use of noninvasive positive pressure ventilation

Has impending respiratory failure

### Altered mental status

Due to hypercarbia or hypoxemia as a result of pneumonia

# When to refer for opinion?

- Slowly resolving pneumonia:
  - Persistence of CXR abnormalities for >1 month in a clinically improved host
- Non-Resolving/ Persistent pneumonia:
  - Persistence of symptoms and CXR abnormalities for >1 month in a child with LRTI
- Recurrent pneumonia:
  - Multiple episodes with evidence of complete resolution in between.
    - <u>></u> 2 episodes within 1yr or
    - > 3 such episodes over any time period

# When to discharge ?

- Respiratory distress has resolved
- No hypoxemia (oxygen saturation, > 90%)
- Feeding well
- Able to take oral medication or have completed a course of parenteral antibiotics
- Parents understand the signs of pneumonia, risk factors and when to return

# Thank You

# Which equipment is most useful for diagnosing pneumonia in children?

• A) Pulse Oximeter and Thermometer



• B) Stethoscope





# What is the most prevalent cause of pneumonia throughout childhood?

A) Streptococcus pneumoniae
B) Mycoplasma pneumoniae
C) Viral infections
D) Haemophilus influenzae type b

# Which of the following investigations are routinely indicated in children with non-severe community-acquired pneumonia?

A) Chest X-rayB) Microbiological investigationsD) Acute phase reactantsE) None of the above


# Clinical Management of Severe Childhood Pneumonia

# Dr Hema Gupta Mittal

Professor and In-charge Division of Pediatric Pulmonology , ABVIMS& RMLH Delhi



### **Definition: Severe Pneumonia : WHO definition**



Danger signs: Grunt, Not able to drink, persistent vomiting, convulsions, lethargic or unconscious, stridor in a calm child or severe malnutrition

# **PRINCIPLES in Management of Severe Pneumonia**

| Assessment and                   | Antibiotics   | Other medications:        |
|----------------------------------|---|---------------------------|
| management of                    | Which, why, when, how                               | Antivirals, nebulization, |
| respiratory distress             | , where   | cough syrups etc          |
| Respiratory and cough<br>hygiene | Monitoring ,<br>Investigations and<br>Complications | Prevention stratergies    |

### Case

- Laxmi, 7 days old baby with
- refusal of feeds , breathing difficulty \* 3 days
- O/E –baby is dull .RR :74/ min . Spo2 : 85%
- Multiple Pustules present over the trunk

#### **Diagnosis ? Treatment ?**

# Antibiotics: Which ?When ??Why??

F

| Bacteria                 | Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus,<br>Mycobacterium tuberculosis, Bordetella pertussis, Klebsiella pneumoniae |
|--------------------------|--|
| Viruses<br>(Most common) | Respiratory Syncytial Viruses, Rhinovirus, Influenza Virus, Human<br>Metapneumovirus, Adeno virus, Measles, CMV, EBV                               |
| Fungi                    | Aspergillus, Candida, Pneumocystis Jirovecii (immunocompromised)   |
| Noninfectious            | Aspiration of food /gastric acid, foreign bodies, hydrocarbons, lipid substances, hypersensitivity reactions, drug or radiation                    |

| Organism & Clues                 |  |  |
|----------------------------------|--|--|
| Staphylococcus:Pyoderma, Measles | Gram negative, Staph aureus: PEM                     |  |
| Pneumocystis:HIV                 | Gram negative, Aspergillus: <mark>Neutropenia</mark> |  |
| Pseudomonas, Staphylococcus: CF  | Anaerobes: Aspiration                                |  |

## **Common Etiology of Pneumonia in children in LMICs**

# Viruses are most common pathogens..

In 2015, RSV & Influenza accounted for 20% & 10% cases, respectively.

The increased use of pneumococcal conjugate vaccine (PCV) and *Haemophilus influenzae type b* (Hib) vaccine has **changed pneumonia etiology**, with *Staphylococcus aureus* and *H. influenzae* non-type b now the commonest bacterial pathogens

# **Differentiating etiologies**

#### **Bacterial**

Viral

More toxic, Rapid progression Lobar pneumonia Complications: Empyema, Abscess Less toxic ,Follows URTI, Gradual ;Wheeze+/-, bronchiolitis ,Usually b/l

#### **Atypical**

Less toxic, "walking pneumonia" Wheezing, diffuse Extra pulmonary manifestations++







Lobar consolidation+ air bronchogram;Patchy/Cavitatory/ Round pneumonia/ Pneumatoceles/ empyema

Diffuse GGO/Interstitial infiltrates/Multifocal patchy consolidation OR Lobar / segmental atelectasis, ARDS

Diffuse interstitial/ reticular pattern /Hilar lymphadenopathy/ Normal chest X-ray

# Antibiotics recommendations: IPD

#### : ANTIBIOTIC THERAPY FOR PNEUMONIA/SEPSIS IN INFANTS <2 MONTHS

| Antibiotic             | Each Dose    | Frequ       | Frequency   |        | Duration |
|------------------------|--------------|-------------|-------------|--------|----------|
|                        | (mg/kg/dose) | < 7days age | > 7days age | ]      | (Days)   |
| Inj. Ampicillin*       | 50           | 12 hourly   | 8 hourly    | IV, IM | 7-10     |
| And Inj.<br>Gentamicin | 5            | 24 hourly   | 24 hourly   | IV, IM | 7-10     |
| Inj. Amikacin          | 15           | 24 hourly   | 24 hourly   | IV, IM | 7-10     |

\*If concomitant meningitis is suspected, the drugs should be given IV and Inj. Cefotaxime 50 mg/kg IV 8 hourly is used instead of Ampicillin. The total duration of therapy in meningitis is 2-3 weeks. In case of suspected staphylococcal infection, Injection Cloxacillin 50mg/kg 8 hourly is to be added to the regime.

#### R 3: Severe pneumonia WHO

1 st line: parenteral ampicillin (or penicillin) and gentamicin\*5d 2<sup>nd</sup> line :Ceftriaxone: if failed on 1<sup>st</sup> line

# Antibiotics recommendations: IPD

F

|                      | Age <2m  | >2m-5y   | >5y   |
|----------------------|--|--|---|
| 1 <sup>st</sup> line | Cefotaxime/Ceftriaxone ± gentamicin/amikacin   | Ampicillin   | Ampicillin  |
| 2 <sup>nd</sup> line | Cefotaxime/Ceftriaxone ±<br>gentamicin/amikacin<br>Piperacillin tazobactam/<br>Cefoperazone sulbactam  | Co -amoxyclav OR<br>Cefotaxime OR ceftriaxone  | Co -amoxyclav OR Cefotaxime OR<br>ceftriaxone or <mark>Azithromycin</mark>  |
| Stap<br>aureus       | Ceftriaxone+ <mark>cloxacillin</mark> OR<br>cefuroxime or Coamoxyclav<br>+gentamicin or amikacin<br><mark>2nd line ceftriaxone</mark><br>+vancomycin/clindamycin | Ceftriaxone+cloxacillin OR<br>cefuroxime or Coamoxyclav<br>or cefazolin<br>2nd line ceftriaxone<br>+vancomycin/clindamycin | Ceftriaxone+cloxacillin OR<br>cefuroxime or Coamoxyclav or<br>cefazolin<br>2nd line ceftriaxone<br>+vancomycin or clindamycin |

# **Characteristics and Management: Staph Pneumonia**

| -  | MSSA   | MRSA   |
|--|--|--|
| Clinical setting<br>Age group<br>Course & outcome<br>complications | Community<br>Higher<br>Less severe<br>Lesser   | Healthcare/community<br>Younger<br>More severe, ICU admissions<br>Higher:pneumatoceles, Pleural effusion |
| Treatment  | Cefazolin (50 mg/kg/d, BD or TID)<br>/Clox (100mg/Kg TID)<br>+/- Aminoglycoside (gentamicin<br>(5–7 mg/kg/d, OD) Or Amikacin<br>(15 mg/kg/d, OD) | Vancomycin (40 mg/Kg/d in QID)<br>/Clindamycin(20 mg/kg/d, TID or QID)<br>Linezolid (10 mg/kg/d), TID    |
| Duration   | 7 to 10 days   | <ul><li>14 d if no complications</li><li>4-6 weeks if complications</li></ul>                            |

## **Viral Pneumonias and Antivirals**


- No effective antivirals available for most viral pneumonias (few exceptions)
- Anti-virals used to treat sporadic or epidemic or pandemic viral pneumonia include: Oseltamivir, Zanamivir, Peramivir, Ribavirin, Remdesivir (off label), Ganciclovir
- Empirical antibiotics **should be** used in severe viral pneumonias in hospitals/ICU
  - Influenza/CMV/Adenovirys/ RSV/ rhino...
  - SARS CoV 2 and Covid 19 : lessons learnt !!!!

# Case 1

- Laxmi, 7 days old baby with
- refusal of feeds , breathing difficulty \* 3 days
- O/E –baby is dull .RR :74/ min . Spo2 : 85%
- Multiple Pustules present over the trunk

#### **Diagnosis ? Treatment ?**

- Admit
- Severe Pneumonia with Sepsis
- Probably Staphylococcal
- Vancomycin plus an aminoglycoside



# **Oxygen therapy**

• Why important: Hypoxia

✓ Common occurrence in pneumonia (severe & complicated)✓ Increases mortality

- Goal: SpO2 > 92-94%
- Indications

Ę

✓ Severe pneumonia(grunting/cyanosis/Severe lower chest in-drawing)
 ✓ Respiratory rate ≥70 breaths/min
 ✓ Hypoxia (Sat <90%)</li>

#### **S** Guidelines

<sup>\*</sup>If oxygen saturation < 90%, refer as Severe Pneumonia or Very Severe Disease

<sup>\*\*</sup>If the child has wheezing, give 3 doses of nebulized salbutamol for 20 minutes; or 2-4 puffs of salbutamol MDI (at a gap of 2-3 min between each puff) with spacer repeated every 20 minutes and if there is improvement continue bronchodilators under monitoring

<sup>\*\*\*</sup> If referral is not feasible or refused, manage with oral amoxicillin twice a day and injection gentamicin once a day for 7 days in consultation with MO PHC and daily assessment (see table 4)

## Methods of oxygen administration

• Heated, humidified oxygen

=

- Nasal prongs or a nasal or nasopharyngeal catheter (no face or head mask)
- Oxygen flow-rate with canula, head box, and face mask ???
- Other devices: CPAP, HHHFNC, Invasive ventilation



# Fluid therapy: why important ?

- Unable to maintain their fluid intake because of breathlessness or fatigue
- Non-severe cases: breast-feeding or oral fluid/feed
- Options in severe case: Naso-gastric or Intravenous fluid therapy
- Indication of IV fluids

F

- ✓ Neonates & young children with severe distress✓ Persistent vomiting
- Monitor fluid balance & serum electrolyte (e.g., Na<sup>+</sup>): *SIADH is likely in severe* & *complicated cases*

### **Other Medications**

#### • Fever


Ţ

 ✓ Paracetamol (@15mg/kg/dose) to keep child comfortable (avoid tepid sponging)

#### • Cough

- ✓ Avoid cough suppressants.
- ✓Intake of adequate fluids.
- ✓ Household remedies (Tulsi, ginger, honey)
- ✓ No role of nebulization

- Vomiting (post-tussive)
  - ✓ Anti-emetics routinely not required✓ If persistent vomiting: anti-emetics
- Maintain proper hydration
- Identifying signs of deterioration/ serious illness and complications
- Access to referral facility (providing a 'safety net')



\*\*If the child has wheezing, give 3 doses of nebulized salbutamol for 20 minutes; or 2-4 puffs of salbutamol MDI (at a gap of 2-3 min between each puff) with spacer repeated every 20 minutes and if there is improvement continue bronchodilators under monitoring

# **Counselling in Pneumonia**

- Counselling to Parents, Family & the Child
- Why Counselling ?

F

- Parents & Children Under stress
- Psychological morbidities (post ICU care)
- -posttraumatic stress disorder, anxiety disorder, depression.
  - Financial stress
  - Worry about recovery & long-term complications
  - **Counselling** about Proper Diet, danger signs, supportive care , follow up etc.
    - Multidisciplinary Approach: most beneficial
      - post-intensive care unit patients.

# Respiratory Hygiene and Cough Etiquette



Cover your mouth and nose with a tissue when coughing or sneezing

Dispose of the tissue afterwards



After coughing


or sneezing, wash

your hands with


soap and water




Wear a mask if you are coughing or sneezing







# Monitoring



. Chest X-ray :All cases of Severe pneumonia, non improving or Diagnostic dilemmna

Blood investigations (CRP, TLC, procalcitonin/ blood culture)
Do not reliably differentiate bacterial vs. viral

For detection of viruses: Polymerase chain reaction (PCR): may be useful
Interpreted with caution, as healthy or in URTI may have positive. Availability and cost

**Chest ultrasound :emerging POC test** 

CHEST CT : NO ROUTINE USE : Suppurative parenchymal complication: abscess/ necrotizing pneumonia/ necrosis, Pleural complications, Diagnostic dilemma

# Case

- 7 yr old Rakesh treated for pneumonia in a district hospital for 10 days with oral antibiotics brought with persistent fever and increasing Respiratory distress
- H/o Lt sided chest pain , dull note and absent breath sounds in Lt infarscapular area.
- Diagnosis ? Drugs of choice ? Duration of therapy ?

- Lt Empyema
- Parenteral
- Cefotaxime or Ceftriaxone plus Clinadamycin

## Non-Response to Initial Empirical Therapy

#### **??Complications**

F

Empyema Abscess

# ??Different pathogen

Mycobacterium tuberculosis Mycoplasma COVID 19 **??Drug resistance** B lactam producing Hib, Drug resistant staph aureus including community acq methicillin resistance

#### **Highest risk factors for childhood Pneumonia deaths in India :2017**



## PROTECT, PREVENT AND TREAT

### **Prevention of Pneumonia**

Childhood immunization (DPT, Hib, PCV, Measles, Influenza)

#### Nutrition

(Breastfeeding, vitamin (A & D) and mineral (Zinc) supplementatio

n

It has been estimated that if PCV13 coverage in lowincome countries would reach the coverage of the DTP3 vaccine, then it could prevent 399,000 child deaths and 54.6 million pneumonia episodes annually

Maternal immunization (Influenza, Pertussis)

F



Pneumonia still highest cause of U5 mortality Globally and India

SEVERE PNEUMONIA:EARLY RECOGNIZION/ APPROPRIATE ANTIBIOTICS/ PULSE OXIMETRY/OXYGEN THERAPY

Non responsive pneumonia: Think COMPLICATIONS!!!

After malnutrition growing pollution (indoor &outdoor): Risk factor

# **IMPACT OF AIR POLLUTION ON CHILDREN**

#### Dr. Harshal Ramesh Salve


MBBS, MD, FIPHA Additional Professor Centre for Community Medicine All India Institute of Medical Sciences, New Delhi Co-ordinator CAPHER India Email: harshalsalve@aiims.edu



-Connect Seriese - MOHFW - January 2025

CAPHER-India

# Why Environmental health?






# Burden of disease attributed environmental exposure

# 24% of diseases and 23% of mortality globally

**CAPHER-India** 



E-Connect Seriese - MOHFW - January 2025

## **Levels of Environmental Risks**

| Level 0 | Level 1                              | Level 2                                   | Level 3   | Level 4                                  |  |
|---------|--------------------------------------|---|---|--|--|
|         |                                      | Unsafe water, sanitation, and handwashing | Unsafe water source                               |  |  |
|         |                                      |   | Unsafe sanitation                                 |  |  |
|         |                                      |   | No handwashing with soap                          |  |  |
|         |                                      | Air pollution                             | Particulate matter pollution                      | Ambient particulate matter pollution     |  |
|         | ental/<br>al risks                   |   |   | Household air pollution from solid fuels |  |
|         |                                      |   | Ambient ozone pollution                           |  |  |
|         | on a                                 | Other environmental risks                 | Residential radon                                 |  |  |
|         | Environmental/<br>occupational risks | Other environmental risks                 | Lead exposure                                     |  |  |
|         |                                      |   | Occupational carcinogens                          |  |  |
|         |                                      | ШS  |   | Occupational asthmagens                  |  |
|         |                                      | Occupational risks                        | Occupational particulate matter, gases, and fumes |  |  |
|         |                                      |   | Occupational noise                                |  |  |
|         |                                      |   | Occupational injuries                             |  |  |
|         |                                      |   | Occupational ergonomic factors                    |  |  |

Global Burden of Disease Study (GBD) risk factor hierarchy (adapted from Stanaway et al. 2018).





### WHO Air Quality Standards - 2021

| Pollutant                 | Averaging time           | 2005 AQGs | 2021 AQG level |
|---------------------------|--------------------------|-----------|----------------|
| PM <sub>2.5</sub> , μg/m³ | Annual                   | 10        | 5              |
| ΡΙνί2.5, μβ/11            | 24-hour <sup>a</sup>     | 25        | 15             |
| DM ug/m <sup>3</sup>      | Annual                   | 20        | 15             |
| PM10, μg/m³               | 24-hour <sup>a</sup>     | 50        | 45             |
| 0. 11/203                 | Peak season <sup>ь</sup> | -         | 60             |
| O₃, μg/m³                 | 8-hour <sup>a</sup>      | 100       | 100            |
| NO ug/m3                  | Annual                   | 40        | 10             |
| NO₂, μg/m³                | 24-hour <sup>a</sup>     | -         | 25             |
| SO <sub>2</sub> , μg/m³   | 24-hour <sup>a</sup>     | 20        | 40             |
| CO, mg/m <sup>3</sup>     | 24-hour <sup>a</sup>     | _         | 4              |

#### **Revision of NAAQ Standards are in process**





## National Ambient Air Quality Standards (2009)

| *         |   |                             | Concentration in Ambient Air                             |                                   |
|-----------|---|-----------------------------|--|-----------------------------------|
| Sr.<br>No | Pollutants  | Time<br>Weighted<br>Average | Industrial,<br>Residential,<br>Rural, and Other<br>Areas | Ecologically<br>Sensitive<br>Area |
| 1         | Sulphur dioxide (SO <sub>2</sub> ),                                 | Annual*                     | 50   | 20                                |
|           | µg/m³   | 24 hours**                  | 80   | 80                                |
| 2         | Nitrogen dioxide (NO <sub>2</sub> ),                                | Annual*                     | 40   | 30                                |
|           | µg/m³   | 24 hours**                  | 80   | 80                                |
| 3         | Particulate matter  | Annual*                     | 60   | 60                                |
|           | (Size <10 $\mu$ m) or PM <sub>10</sub> $\mu$ g/m <sup>3</sup>       | 24 hours**                  | 100  | 100                               |
| 4         | Particulate matter  | Annual*                     | 40   | 40                                |
|           | (Size<2.5 μm) or PM <sub>2.5</sub> μg/m <sup>3</sup>                | 24 hours**                  | 60   | 60                                |
| 5         | Ozone ( $O_3$ ), $\mu g/m^3$  | 8 hours**                   | 100  | 100                               |
|           |   | 1 hours **                  | 180  | 180                               |
| 6         | Lead (Pb), µg/m <sup>3</sup>  | Annual*                     | 0.50   | 0.50                              |
|           |   | 24 hours**                  | 1.0  | 1.0                               |
| 7         | Carbon monoxide (CO),   | 8 hours**                   | 02   | 02                                |
|           | mg/m <sup>3</sup>   | 1 hours **                  | 04   | 04                                |
| 8         | Ammonia (NH <sub>3</sub> ), µg/m <sup>3</sup>                       | Annual*                     | 100  | 100                               |
|           |   | 24 hours**                  | 400  | 400                               |
| 9         | Benzene (C6 H6), µg/m <sup>3</sup>                                  | Annual*                     | 05   | 05                                |
| 10        | Benzo(a) pyrene (BaP)-<br>particulate phase only, ng/m <sup>3</sup> | Annual*                     | 01   | 01                                |
| 11        | Arsenic (As), ng/m <sup>3</sup>                                     | Annual*                     | 06   | 06                                |
| 12        | Nickel (Ni), ng/m <sup>3</sup>                                      | Annual*                     | 20   | 20                                |

**Ecologically sensitive areas:** 

Areas in which developmental activities is prohibited. Eg:-Murud-Janjira , Dahanu, Mahabaleshwar-Panchgani, Sultanpur etc.



#### **MAJOR AIR POLLUTANTS**

|                              | Classification                  | Examples   |
|------------------------------|---------------------------------|--|
| Based on source<br>of origin | Natural air<br>pollutants       | dust, sea-salt, forest fires   |
|                              | Anthropogenic air<br>pollutants | stationary point sources, mobile sources, waste<br>disposal landfills, controlled burning etc  |
| Based on method<br>of origin | Primary air<br>pollutants       | Sulphur dioxide ( <b>SO</b> <sub>2</sub> ), Carbon monoxide ( <b>CO</b> ),<br>Lead ( <b>Pb</b> ), Ammonia ( <b>NH</b> <sub>3</sub> ) |
|                              | Secondary air<br>pollutants     | <b>Ozone</b> , Nitrogen dioxide ( <b>NO<sub>2</sub>)</b> ,<br>Photochemical smog   |
| Based on<br>chemical         | Gaseous air<br>pollutants       | $SO_2$ , $NO_X$ , $O_3$ , $CO$   |
| composition                  | Particulate air<br>pollutants   | PM10, PM2.5, PM1   |
| CAPHER-India                 | (                               | CREST PURVIEW  |

गरीरमाहां खल

# Why there is need to take the action on Air Pollution effects?

Responsible for One in every eight death in India <sup>1</sup> Second most common leading risk factor (DALY) in India<sup>2</sup>

99% of India's population

exposed to more than

recommended ( $10 \mu g/m^3$ )

1. India State-Level Disease Burden Initiative Collaborators Nations within a nation: variations

in epidemiological transition across the states of India, 1990-2016 in the Global Burden of Disease Study, Lancet, 2017 Dec 2;390(10111):2437-2460. doi: 10.1016/S0140-6736(17)32804-0. Epub 2017. 14

2. Gorai AK, Tchounwou PB, Biswal SS, Tuluii F.Spatio-Temporal Variation of Particulate Matter(PM<sub>2.5</sub>) Concentrations and Its Health Impacts in a Mega City, Delhi in India.Environ Health Insights. 2018 Aug 19;12:1178630218792861. doi: 10.1177/1178630218792861. eCollection 2018 Ai S, Qian ZM, Guo Y, Yang Y, Rolling CA, Liu E, et al Long-term exposure to ambient fine particules associated with asthma: A cross-sectional study among older adults in six low- and middle-income countries.


Environ Res. 2019 Jan;168:141-145. doi: 10.1016/j.envres.2018.09.028. Epub 2018 Sep 24.

ay A, Dey S, Chowdhury S, Goyal P, Expected health benefits from mitigation of emissions from major anthropogenic PM2.3 sources in India: Statistics at state level. Environ Pollut. 2018 Nov;242(Pt B):1817-1826. doi: 10.1016/j.envpol.2018.07.085. Epub 2018 Jul 24





### Variety of impacts





Source: https://www.epa.gov/benmap/how-benmapce-estimates-health-and-economic-effects-air-polity




### Air Pollution and Child mortality

2<sup>nd</sup> leading risk factor for deaths in children under 14 years

16% of all deaths in children


**CAPHER**-India






Pandey, A, Michael Brauer, Maureen L. Cropper, Kalpana Balakrishnan, Prashant Mathur, Sagnik Dey, Burak Turkgulu, et al. . Health and Economic Impact of Air Pollution in the States of India: The Global Burden of Disease Study 2019. The Lancet Planetary Health. 2021,5 (1): e25–38. https://doi.org/10.1016/S2542-5196(20)30298-9.

### Air Pollution and Child mortality





State wise and urban/rural disparity exists





#### Exposure of Air Pollution in Intra – Uterine life

- Low birth weight and preterm birth are leading risk factors for death in the first month of life.
- India ->exposure to air pollution was linked to the deaths of 116,000 infants within the first month of being born.
- Archana Patel et al (2015) increased risk of perinatal mortality among households using polluting fuels (adjusted relative risk (aRR) 1.44, 95 % CI 1.30-1.61)
- A study in Chennai, that a 10 µg/m<sup>3</sup> increase during pregnancy was associated with a 4 g (95% CI:1.08 g, 6.76 g) decrease in birth-weight

Ghosh R, Causey K, Burkart K, Wozniak S, Cohen A, Brauer M. Ambient and household PM2. 5 pollution and adverse perinatal outcomes: A meta-regression and analysis of attributable global burden for 204 countries and territories. PLoS medicine. 2021 Sep 28;18(9):e1003718.

Balakrishnan K, Ghosh S, Thangavel G, Sambandam S, Mukhopadhyay K, Puttaswamy N, Sadasivam A, Ramaswamy P, Johnson P, Kuppuswamy R, Natesan D. Exposures to fine particulate matter (PM2, 5) and birthweight in a rural-urban, mother-child cohort in Tamil Nadu, India. Environmental research. 2018 Feb 1;161:524-31.

Patel AB, Meleth S, Pasha O, Goudar SS, Esamai F, Garces AL, Chomba E, McClure EM, Wright LL, Koso-Thomas M, Moore JL, Saleem S, Liechty EA, Goldenberg RL, Derman RJ, Hambidge KM, Carlo WA, Hibberd PL. Impact of exposure to cooking fuels on stillbirths, perinatal, very early and late neonatal mortality - a multicenter prospective cohort study in rural communities in India, Pakistan, Kenya, Zambia and Guatemala. Matern Health Neonatol Perinatol. 2015 Jul 21;1:18.





# Exposure of air pollution during childhood




Figure 3:: Distribution of lower respiratory infection (LRI) deaths in 2019 linked to PM2.5 and household air pollution, by age (years, except early neonatal [0 to 6 days] and late neonatal [7 to 27 days]).

- Exposure to air pollution reduce lung function among children
- Continuous exposure to (PM10, PM2.5 nitrogen dioxide) can cause respiratory infections among children





# Exposure of air pollution during childhood

#### • Short term exposure

- Ear, nose, and throat irritation
- Aggravated conditions such as allergies and asthma
- Eczema

**CAPHER**-India



#### • Long term exposure


- New cases of childhood asthma
- Increase the risk of developing chronic respiratory diseases such as COPD during adulthood
- Childhood anaemia
- Allergic rhinitis
- Neurodevelopmental outcomes
- Stunting in children

Salvi SS, Kumar A, Puri H, Bishnoi S, Asaf BB, Ghorpade D, Madas S, Agrawal A, Kumar A. Association between air pollution, body mass index, respiratory symptoms, and asthma among adolescent school children living in Delhi, India. Lung India. 2021 Sep-Oct;38(5):408-415. doi: 10.4103/lungindia\_955\_20. PMID: 34472517; PMCID: PMC8509169.






# Determinants of the health impacts related to air pollution in children





#### **Recommendations**











#### **Addreesing Air Pollution and NCDs**





#### **Domains for Action**





#### AIIMS - IIT Delhi collaboration – Capitalizing on strengths



Strengths

**CAPHER-India** 

- Epidemiology
- Medical Sciences
- Running Cohort
- Network development



Strengths

- Exposure measurement
- Technology use and GIS
- Modeling

#### Institutional mechanism is key for sustainability



### AIIMS – IIT Study at Ballabgarh

Mortality burden of ambient PM<sub>2.5</sub> exposure in Delhi NCR

(CCM, AIIMS - IIT Delhi Joint Project)

#### **Objectives**

Development of a mortality model by collating cause-specific mortality data and generating high-resolution PM<sub>2.5</sub> exposure data for Delhi NCR


Estimate mortality burden due to shortterm exposure to ambient PM<sub>2.5</sub> in Delhi NCR

|                         | IRR   | p-value | 95% Confidence Interval |       |
|-------------------------|-------|---------|-------------------------|-------|
| Total deaths            | 1.105 | 0.000   | 1.068                   | 1.144 |
| Respiratory<br>Diseases | 1.026 | 0.353   | .971                    | 1.085 |
| CVD                     | 1.043 | 0.127   | .988                    | 1.102 |

PI - Harshal Ramesh Salve (AIIMS) – Sagnik Dey (IIT D)



#### PM 2.5 Exposure and OPD consultation for Cardio-respiratory illness – CRHSP Ballabgarh




PM 2.5 (7 day Lag) IRR – 1.02 (1.01 – 1.04)




## **Sources of Air Pollution data**

- Reference-grade monitoring network (PM<sub>2.5</sub>, PM<sub>10</sub>, SO<sub>2</sub>, NO<sub>2</sub>, O<sub>3</sub>, Benzene, CO, etc.); expected to double by 2024 under the National Clean Air Programme (NCAP)
- Satellite-based PM<sub>2.5</sub> database at 1 km (other pollutants: NO<sub>2</sub>, SO<sub>2</sub>, O<sub>3</sub> etc.)
- Other networks like BC from IMD and ISRO; MAPAN and SAFAR networks
- Personal exposure monitoring in indoor microenvironments from past and existing cohorts

**CAPHER-India** 



### **Sources of Air Pollution data**



#### https://cpcb.nic.in





#### **Collaborative for Air Pollution and Health Effects Research-India**

#### **Objectives**

- To build partnerships among research institutions to develop and implement research studies on health effects of air pollution
- To facilitate development of collaborative research proposals to fill critical evidence gaps
- To conduct capacity building exercises/programs targeted at early career researchers





#### **Capher-India: Steering Committee**



Dr. Anand Krishnan All India Institute of Medical Sciences New Delhi



Dr. Kalpana Balakrishnan Shri Ramchandra Institute of Higher Education and Research Chennai



Dr. Santu Ghosh St John Medical College, Bengaluru



CAPHER Aggajita Chattopadhyay Indian Institute of Population Sciences, Mumbai IDP Climate Studies, IIT Bombay



#### **Capher-India: Secretariat**







Dr. Harshal Ramesh Salve, AllMS New Delhi Dr. Sagnik Dey, IIT Delhi Dr. Surbhi Kapoor Research Scientist, AlIMS New Delhi

Secretariat office: #40, Centre for Community Medicine, old OT Block, All India Institute of Medical Sciences, Ansari Nagar New Delhi-110029 Email: <u>capherindia@gmail.com</u>, Ph: 91-11-26593366 E-Connect Seriese - MOHEW - January 2025



#### CAPHER – India – Air Health Bulletin



Year 2021 - 22

CAPHER-India

Year 2022 - 23

Year 2023 - 24



**CREST PURVIEW** 

#### How to join CAPHER – India network

- Find us on Twitter for updates on CAPHER activities and upcoming events
- Write to the secretariatcapherindia@gmail.com
- To join the network, please complete the form https://tinyurl.com/CAPHERIndia

#### 🍀 CAPHER-India

**Collaborative for Air Pollution and** Health Effects Research-India



AIIMS - IIT Delhi collaboration

#### CAPHER Secretariat

Room No. 40, Centre for Community Medicine, Old O.T. Block All India Institute of Medical Sciences (AIIMS), New Delhi, India

Funding Support - Health Effect Institute (HEI), Boston USA





E-Connect Seriese - MOHFW - January 2025

CAPHER-India OLLUTION AND HEALTH IN INDIA-CURRENT EVIDENCE TO INFORM THE INDIA NAAQS REVSION PROCESS

### **Challenges** ahead

Changing priorities of policy makers

Lack of opportunities for integration

Geographically restrictive approach

• Medium, long term goals are missing - Mostly A knee jerk

reaction is observed










#### **Capacity building of Health officials**



# Centre for Excellence for Cardiopulmonary diseases under NPCCHH








Developed Training manual for State and District level officers in CC and Cardiorespiratory diseases





#### Actions needed at programme level



National Programme for Climate Change and Human Health (NPCCHH)



E-Connect Seriese - MOHFW - January 2025

**CAPHER**-India

## Specific actions at policy level

- Integration of health and environmental measures policy decisions serve to protect and improve health
- End health harmful subsidies
- Develop healthy and efficient transport options, such as combining rapid transit with walking/cycling
- Invest in health and evidence generation
- Provide safe housing conditions
- Regulate potentially health-harmful industries
- Select energy options, while considering health impacts and their financial implications





## **Specific actions at individual level**

Decongestion of traffic by using Public transport and environment friendly vehicles










Air quality monitoring



Balanced diet with more consumption of fruits and vegetables




Use of N95 Mask




**CAPHER**-India



Efficient use of energy, use of clean fuel



Tree Plantation and conservation






### **The Way Forward**

- Continued Knowledge and skill enhancement of the self –
   Contribution in Science by generating local evidence
- Involvement of Medical colleges/ institutions
- Understand and priorities the local environmental risks and community needs
- Strategic communication to the Policy makers
- Strengthening of Programme

CAPHER-India

Collaboration and Partnership





#### Passion, Perseverance and Partnership are essential for essential for advancing science

## ogether we Achieve More

#### THANK - YOU



